The potential therapeutic and prognostic impacts of the c-MET/HGF signaling pathway in colorectal cancer

被引：48

作者：

Parizadeh, Seyed Mostafa ^{[1
]}

Jafarzadeh-Esfehani, Reza ^{[2
]}

Fazilat-Panah, Danial ^{[3
]}

Hassanian, Seyed Mahdi ^{[1
]}

Shahidsales, Soodabeh ^{[3
]}

Khazaei, Majid ^{[1
]}

Parizadeh, Seyed Mohammad Reza ^{[1
]}

Ghayour-Mobarhan, Majid ^{[1
]}

Ferns, Gordon A. ^{[4
]}

Avan, Amir ^{[1
,5
]}

机构：

[1] Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Mashhad, Razavi Khorasan, Iran

[2] Mashhad Univ Med Sci, Dept Med Genet, Fac Med, Mashhad, Razavi Khorasan, Iran

[3] Mashhad Univ Med Sci, Canc Res Ctr, Mashhad, Razavi Khorasan, Iran

[4] Brighton & Sussex Med Sch, Div Med Educ, Brighton, E Sussex, England

[5] Mashhad Univ Med Sci, Student Res Comm, Fac Med, Mashhad, Razavi Khorasan, Iran

来源：

IUBMB LIFE | 2019年 / 71卷 / 07期

关键词：

c-MET; HGF signaling pathway; therapeutic; prognostic; colorectal cancer; HEPATOCYTE GROWTH-FACTOR; PRIMARY COLON-CANCER; WILD-TYPE KRAS; MET EXPRESSION; FACTOR RECEPTOR; LIVER METASTASIS; OVEREXPRESSION; STAGE; COMBINATION; ACTIVATION;

D O I：

10.1002/iub.2063

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Colorectal cancer (CRC) is the third most common cancer and a common cause of cancer-related mortality globally. In spite of the improvements in the early diagnosis of CRC, approximately one-third of patients develop metastasis and then have a very poor survival rate. The mesenchymal-epithelial transition factor (c-MET) is a tyrosine kinase cell surface receptor activated by hepatocyte growth factor (HGF). Activation of c-MET/HGF signaling pathway regulates a variety of biological processes including cell motility, cell proliferation, angiogenesis, the epithelial-to-mesenchymal transition, and the development and progression of cancer cells. Recent studies have suggested that the c-MET/HGF signaling pathway is involved in the carcinogenesis of CRC. In this review, we summarize the main findings of recent studies investigating the role of c-MET/HGF signaling pathway in CRC and the potential of the c-MET/HGF signaling pathways in the diagnosis and treatment of CRC. (c) 2019 IUBMB Life, 2019

引用

页码：802 / 811

页数：10

共 81 条

[11] Worldwide Variations in Colorectal Cancer [J].

Center, Melissa M. ;

Jemal, Ahmedin ;

Smith, Robert A. ;

Ward, Elizabeth .

CA-A CANCER JOURNAL FOR CLINICIANS, 2009, 59 (06) :366-378

[12] Dual inhibition of EGFR and c-Met kinase activation by MJ-56 reduces metastasis of HT29 human colorectal cancer cells [J].

Chen, Hui-Jye ;

Jiang, Yi-Lin ;

Lin, Chung-Ming ;

Tsai, Shih-Chang ;

Peng, Shu-Fen ;

Fushiya, Shinji ;

Hour, Mann-Jen ;

Yang, Jai-Sing .

INTERNATIONAL JOURNAL OF ONCOLOGY, 2013, 43 (01) :141-150

[13] Mecp2-mediated Epigenetic Silencing of miR-137 Contributes to Colorectal Adenoma-Carcinoma Sequence and Tumor Progression via Relieving the Suppression of c-Met [J].

Chen, Tao ;

Cai, Shi-Lun ;

Li, Jian ;

Qi, Zhi-Peng ;

Li, Xu-Quan ;

Ye, Le-Chi ;

Xie, Xiao-Feng ;

Hou, Ying-Yong ;

Yao, Li-Qing ;

Xu, Mei-Dong ;

Zhou, Ping-Hong ;

Xu, Jian-Min ;

Zhong, Yun-Shi .

SCIENTIFIC REPORTS, 2017, 7

[14] Drug development of MET inhibitors: targeting oncogene addiction and expedience [J].

Comoglio, Paolo M. ;

Giordano, Silvia ;

Trusolino, Livio .

NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (06) :504-516

[15] Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer [J].

Coppede, Fabio ;

Lopomo, Angela ;

Spisni, Roberto ;

Migliore, Lucia .

WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (04) :943-956

[16]

DIRENZO MF, 1995, CLIN CANCER RES, V1, P147

[17] A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy [J].

Eng, Cathy ;

Bessudo, Alberto ;

Hart, Lowell L. ;

Severtsev, Aleksey ;

Gladkov, Oleg ;

Mueller, Lothar ;

Kopp, Mikhail V. ;

Vladimirov, Vladimir ;

Langdon, Robert ;

Kotiv, Bogdan ;

Barni, Sandro ;

Hsu, Ching ;

Bolotin, Ellen ;

von Roemeling, Reinhard ;

Schwartz, Brian ;

Bendell, Johanna C. .

INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (01) :177-186

[18] Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors [J].

Frampton, Garrett M. ;

Ali, Siraj M. ;

Rosenzweig, Mark ;

Chmielecki, Juliann ;

Lu, Xinyuan ;

Bauer, Todd M. ;

Akimov, Mikhail ;

Bufill, Jose A. ;

Lee, Carrie ;

Jentz, David ;

Hoover, Rick ;

Ou, Sai-Hong Ignatius ;

Salgia, Ravi ;

Brennan, Tim ;

Chalmers, Zachary R. ;

Jaeger, Savina ;

Huang, Alan ;

Elvin, Julia A. ;

Erlich, Rachel ;

Fichtenholtz, Alex ;

Gowen, Kyle A. ;

Greenbowe, Joel ;

Johnson, Adrienne ;

Khaira, Depinder ;

McMahon, Caitlin ;

Sanford, Eric M. ;

Roels, Steven ;

White, Jared ;

Greshock, Joel ;

Schlegel, Robert ;

Lipson, Doron ;

Yelensky, Roman ;

Morosini, Deborah ;

Ross, Jeffrey S. ;

Collisson, Eric ;

Peters, Malte ;

Stephens, Philip J. ;

Miller, Vincent A. .

CANCER DISCOVERY, 2015, 5 (08) :850-859

[19]

Fujisaki T, 1999, CANCER RES, V59, P4427

[20] High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis [J].

Gao, HeLi ;

Guan, Mei ;

Sun, Zhao ;

Bai, ChunMei .

TUMOR BIOLOGY, 2015, 36 (02) :515-520

← 1 2 3 4 5 6 7 8 9 →